Comparison · NCT04544293-sae
Molgramostim vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Molgramostim vs Placebo: serious adverse events. Trial comparisons, record NCT04544293-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04544293-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.173 | 0.106 | 0.269 | wilson | |
| Risk in group 2 | 0.241 | 0.162 | 0.343 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0681 | -0.19 | 0.0568 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.717 | 0.39 | 1.32 | log | |
| Odds ratio, group 1 over group 2 | 0.658 | 0.306 | 1.41 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Molgramostim than on Placebo | 14.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Molgramostim | Double-blind treatment with molgramostim nebulizer solution 300 µg once daily for 48 weeks~Molgramostim: Molgramostim 300 µg nebulizer solution~79 subjects completed double-blind treatment and continued in the open-label extension. The open-label study is still ongoing. | 14 | 81 | EG000 |
| Group 2 | Placebo | Double-blind treatment with placebo nebulizer solution once daily for 48 weeks~Placebo: Matching placebo nebulizer solution~81 subjects completed double-blind treatment and enrolled in the open-label extension. The open-label study is still ongoing. | 20 | 83 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events during double-blind treatment (48 Weeks)
Source ClinicalTrials.gov
Trial
- Title
- Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
- NCT number
- NCT04544293
- Phases
- PHASE3
- Conditions
- Autoimmune Pulmonary Alveolar Proteinosis
- Interventions
- Molgramostim, Placebo, Molgramostim Open-label
- Lead sponsor
- Savara Inc.
- Results first posted
- 2025-08-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04544293?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04544293-sae